Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invitro InternationalIVRO +1.33% PB Ratio is 0.89 as of Aug. 03, 2026, which is 21% below its 10-year median of 1.13. The stock has 1 warning sign investors should review. Among 195 Medical Diagnostics & Research companies, Invitro International ranks better than 84.1% on this metric.
Invitro International stock PB Ratio (=0.8) is close to 2-year low of 0.74.
The historical rank and industry rank for Invitro International's PB Ratio or its related term are showing as below:
IVRO'
s PB Ratio Range Over the Past 10 Years
Min: 0.74 Med: 1.13 Max: 2
Current: 0.85
During the past 9 years, Invitro International's highest PB Ratio was 2.00. The lowest was 0.74. And the median was 1.13.
IVRO's PB Ratio is ranked better than 84.1% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.07
vs IVRO: 0.85
During the past 3 years, the average Book Value Per Share Growth Rate was -31.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -34.60% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Invitro International was 42.70% per year. The lowest was -47.20% per year. And the median was -27.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Invitro International's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invitro International PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invitro International's PB Ratio distribution charts can be found below:
* The bar in red indicates where Invitro International's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Invitro International (IVRO) has a PB Ratio of 0.89 as of Aug. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Invitro International and its competitors. This is 21% below median its historical median of 1.13. Over the past decade, Invitro International's PB Ratio has ranged from 0.74 to 2.00. According to the industry distribution chart, Invitro International ranks #31 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 15.9%.
Is Invitro International's PB Ratio too high?
Invitro International's current PB Ratio of 0.89 is 21% below median its 10-year median of 1.13. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 2.00. The Medical Diagnostics & Research industry median PB Ratio is 2.07. Invitro International's value of 0.89 is 57% below this industry median. Based on the distribution chart, Invitro International ranks #31 out of 195 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Invitro International's PB Ratio compare to IDTA and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, Invitro International ranks #31 out of 195 companies for PB Ratio. This places Invitro International in the top 16% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.07. Invitro International's value of 0.89 is 57% below this benchmark. Historically, Invitro International's own PB Ratio has ranged from 0.74 to 2.00 over the past decade. While the company's 10-year median is 1.13 vs. the industry median of 2.07, Invitro International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.07, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invitro International's current PB Ratio of 0.89 is 57% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Invitro International and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invitro International's current PB Ratio is 0.89, which is 21% below median its own 10-year median of 1.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 35.8% above its estimated fair value. The current PB Ratio is 0.89, which is 21% below median its 10-year median of 1.13 and 57% below the Medical Diagnostics & Research industry median of 2.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Invitro International (IVRO), the current PB Ratio is 0.89 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVRO has been successfully added to your 
